Reason for request
The actual clinical benefit of this vaccine is major in the populations recommended by the Haut Conseil de la santé publique.
Improvement in actual benefit
The pneumococcal vaccine PREVENAR 13 is to replace PREVENAR (7-valent). In this situation, PREVENAR 13 retains the class I improvement in actual benefit (IAB) (major advance in treatment) allocated in 2002 to PREVENAR (7-valent) by the Transparency Committee for prevention of invasive infection caused by Streptococcus pneumoniae (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F) in the treatment of children for whom immunisation is recommended by the Haut Conseil de la santé publique.
For the prevention of acute otitis media and pneumo nia without microbiological confirmation of the diagnosis, PREVENAR 13 retains the lack of improvement in actual clinical benefit (IAB class V) allocated to PREVENAR (7-valent) in 2009 for the treatment of children who the Haut Conseil de la santé publique 10 recommends should be immunised.